Browse result page of B3Pdb
The total number entries retrieved from this search are 235, scroll left/right for detailed information.
| B3pdbIDb3pdb_0002 | PEPTIDE NAMETf-PFV | PEPTIDE SEQUENCE (1-letter)PFVYLI | PEPTIDE SEQUENCE (3-letter)ProPheValTyrLeuIle | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH6 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)O | CELL LINEGlioblastoma (U87), brain endothelial (bEnd.3), an | In vitro CONCENTRATIONNA | In vitro METHODBy measuring the flux of sodium fluorescence (Na-F) and TEER | In vitro RESULTThe transport of Tf-PFV liposomes across the endothelial barrier layer into tumor grown in the porou | ANIMAL MODELIn vitro brain model | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONThe dual functionalized liposomes showed significantly higher cellular uptake as well as increased t | TRANSPORT TYPETranscytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombination with the transferrin protein | PHYSICAL CONDITIONGlioblastoma multiforme | RESPONSENA | RESULTNA | LABELNA | PMID 30261346 |
| B3pdbIDb3pdb_0006 | PEPTIDE NAMENR2B9c | PEPTIDE SEQUENCE (1-letter)KLSSIESDV | PEPTIDE SEQUENCE (3-letter)LysLeuSerSerIleGluSerAspVal | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH9 | PEPTIDE CONFORMATIONNA | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESN[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(C(C)C)C(=O)O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELRat | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntranasal | In vivo METHODHPLC-MS/MS | In vivo RESULTNR2B9c-WGA-NPs are able to bypass the BBB and effectively transport NR2B9c into the brain and neuron | ACTIONIt can protect neurons against excitotoxicity, reduce ischemic brain injury and ameliorate neurologi | TRANSPORT TYPEtranscytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNR2B9c is combined with WGA-modified nanoparticles | PHYSICAL CONDITIONischemic stroke | RESPONSENA | RESULTNA | LABELNA | PMID 30428334 |
| B3pdbIDb3pdb_0007 | PEPTIDE NAMED-T7 | PEPTIDE SEQUENCE (1-letter)HRPYIAHC | PEPTIDE SEQUENCE (3-letter)HisArgProTyrIleAlaHisCys | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Cysteine on C-terminal | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CS)C(=O)O | CELL LINEbEnd.3 and c6 cells | In vitro CONCENTRATIONNA | In vitro METHODConfocal microscopy | In vitro RESULTIt crosses the BBB. | ANIMAL MODELMice | In vivo CONCENTRATIONPTX-1.7 mg/kg, CD-3.6 mg/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIOND-T7 Peptide Modified PEGylated Bilirubin Nanoparticles Loaded with Cediranib and Paclitaxel for Ant | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with Cediranib and Paclitaxel. | PHYSICAL CONDITIONGlioma | RESPONSEStability/half life | RESULT3.31-fold higher than saline | LABELNA | PMID 30525386 |
| B3pdbIDb3pdb_0040 | PEPTIDE NAMEAEP-dendron | PEPTIDE SEQUENCE (1-letter)LRKLRKRLLR | PEPTIDE SEQUENCE (3-letter)LeuArgLysLeuArgLysArgLeuLeuArg | N-TERMINAL MODIFICATIONAEP attached at N-terminal | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH10 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEApoE protein | SMILESN[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)O | CELL LINEbEnd.3 Cell Line | In vitro CONCENTRATION50000 cells per cm square | In vitro METHODLaser Scanning Confocal Microscopy (LSCM) | In vitro RESULTLSCM showed the cellular uptake of the RMT-competent AEP-dendron. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONSuccessful synthesis of dendronised carrier systems with the potential to act as carriers for improv | TRANSPORT TYPEReceptor-mediated transcytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONComined | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 30972332 |
| B3pdbIDb3pdb_0050 | PEPTIDE NAMEDeltorphan | PEPTIDE SEQUENCE (1-letter)YAFDVVG | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Ala-Phe-Asp-Val-Val-Gly-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(C(C)C)C(=O)NCC(=O)O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODConfocal microscopy | In vivo RESULTPresence of engineered nano particles within the brain parenchyma with particular focus on hippocamp | ACTIONOpioid-derived peptides featured by specific helix-like conformation as possible ligands to engineer | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONCNS parenchyma | COMBINATIONComined | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32479916 |
| B3pdbIDb3pdb_0051 | PEPTIDE NAMESLS | PEPTIDE SEQUENCE (1-letter)SLSHSPQ | PEPTIDE SEQUENCE (3-letter)SerLeuSerHisSerProGln | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONCyclic | PEPTIDE NATURENeutral | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(CO)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CO)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)O | CELL LINEhCMEC/D3 cell monolayers | In vitro CONCENTRATION200000 cells per well | In vitro METHODConfocal microscopy | In vitro RESULTIt promoted phage permeation across the hCMEC/D3 cell monolayer. | ANIMAL MODELMice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODPlaque formation assay | In vivo RESULTCyclic SLS peptide facilitated phage permeation across the mouse BBB in vivo | ACTIONBBB-permeable cyclic SLS heptapeptide for brain delivery of macromolecules via macropinocytosis and | TRANSPORT TYPEMacropinocytosis | SUBCELLULAR LOCALISATIONBrain parenchyma | COMBINATIONCombined with M13 phage | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32135226 |
| B3pdbIDb3pdb_0055 | PEPTIDE NAMETfr2 | PEPTIDE SEQUENCE (1-letter)HAIYPRH | PEPTIDE SEQUENCE (3-letter)HisAlaIleTyrProArgHis | N-TERMINAL MODIFICATIONFAM is conjgated at the N-terminal | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)O | CELL LINEbEnd.3 cells | In vitro CONCENTRATIONNA | In vitro METHODImmunofluorescence microscopy | In vitro RESULTIt shows the permeability towards the BBB. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONThese novel peptide conjugates have the capacity to act as promising brain shuttles | TRANSPORT TYPEReceptor-mediated transcytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32055384 |
| B3pdbIDb3pdb_0066 | PEPTIDE NAMEHAVN1 | PEPTIDE SEQUENCE (1-letter)SHAVSS | PEPTIDE SEQUENCE (3-letter)SerHisAlaValSerSer | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH6 | PEPTIDE CONFORMATIONCyclic | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(CO)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CO)C(=O)O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntracerebral ventricular | In vivo METHODMass Spectromtery | In vivo RESULTIt is able to deliver an IRdye800CW-labeled IgG monoclonal antibody into the brain. | ACTIONSynthesized novel cyclic peptides are able efectively modulate the BBB to enhance the delivery of mA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with monoclonal antibody | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 31683745 |
| B3pdbIDb3pdb_0068 | PEPTIDE NAMELinear ADTHAV | PEPTIDE SEQUENCE (1-letter)TPPVSHAV | PEPTIDE SEQUENCE (3-letter)ThrProProValSerHisAlaVal | N-TERMINAL MODIFICATIONAcetylaed at N-terminal | C-TERMINAL MODIFICATION Amide group is attached at C-terminal | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])([C@]([H])(O)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C(C)C)C(=O)O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntracerebral ventricular | In vivo METHODMass Spectromtery | In vivo RESULTIt is able to deliver an IRdye800CW-labeled IgG monoclonal antibody into the brain. | ACTIONSynthesized novel cyclic peptides are able efectively modulate the BBB to enhance the delivery of mA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with monoclonal antibody | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 31683745 |
| B3pdbIDb3pdb_0069 | PEPTIDE NAMECyclic ADTHAV | PEPTIDE SEQUENCE (1-letter)TPPVSHAV | PEPTIDE SEQUENCE (3-letter)ThrProProValSerHisAlaVal | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONCyclic | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])([C@]([H])(O)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C(C)C)C(=O)O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntracerebral ventricular | In vivo METHODMass Spectromtery | In vivo RESULTIt is able to deliver an IRdye800CW-labeled IgG monoclonal antibody into the brain. | ACTIONSynthesized novel cyclic peptides are able efectively modulate the BBB to enhance the delivery of mA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with monoclonal antibody | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 31683745 |
| B3pdbIDb3pdb_0070 | PEPTIDE NAMEADTC5 | PEPTIDE SEQUENCE (1-letter)CDTPPVC | PEPTIDE SEQUENCE (3-letter)CysAspThrProProValCys | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION Amide group is attached at C-terminal | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONCyclic | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(CS)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CS)C(=O)O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntracerebral ventricular | In vivo METHODMass Spectromtery | In vivo RESULTIt is able to deliver an IRdye800CW-labeled IgG monoclonal antibody into the brain. | ACTIONSynthesized novel cyclic peptides are able efectively modulate the BBB to enhance the delivery of mA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined with monoclonal antibody | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 31683745 |
| B3pdbIDb3pdb_0073 | PEPTIDE NAMEDelta-sleep inducing | PEPTIDE SEQUENCE (1-letter)WAGGDASGE | PEPTIDE SEQUENCE (3-letter)Trp- Ala - Gly - Gly - Asp - Ala- Ser - Gly - Glu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH9 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINEBrain | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale albino adult rats | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODRIA, TLC | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 583452, 3840534 |
| B3pdbIDb3pdb_0074 | PEPTIDE NAMEDelta-sleep inducing | PEPTIDE SEQUENCE (1-letter)WAAGDASGE | PEPTIDE SEQUENCE (3-letter)Trp- Ala - D-Ala - Gly - Asp - Ala- Ser - Gly - Glu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH9 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESN[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCC(=O)O)C(=O)O | CELL LINEBrain | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale albino adult rats | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODRIA, TLC | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 583452 |
| B3pdbIDb3pdb_0075 | PEPTIDE NAMEDelta-sleep inducing | PEPTIDE SEQUENCE (1-letter)WAGADASGE | PEPTIDE SEQUENCE (3-letter)Trp- Ala - Gly - D-Ala - Asp - Ala- Ser - Gly - Glu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH9 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESN[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCC(=O)O)C(=O)O | CELL LINEBrain | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale albino adult rats | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODRIA, TLC | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 583452 |
| B3pdbIDb3pdb_0076 | PEPTIDE NAMEDelta-sleep inducing | PEPTIDE SEQUENCE (1-letter)AGADASGE | PEPTIDE SEQUENCE (3-letter)Ala - Gly - D-Ala - Asp - Ala- Ser - Gly - Glu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESN[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCC(=O)O)C(=O)O | CELL LINEBrain | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale albino adult rats | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODRIA, TLC | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 583452 |
| B3pdbIDb3pdb_0150 | PEPTIDE NAMEMMP-2200 | PEPTIDE SEQUENCE (1-letter)Y-D-TGFLS(β-O-Glc)-CONH2 | PEPTIDE SEQUENCE (3-letter)Tyr-D-Thr-Gly-Phe-Leu-Ser(β-O-Glc)-CONH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONGlycosylated serine residue | PEPTIDE LENGTH6 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELAdult Sprague-Dawley rats | In vivo CONCENTRATION10mg/Kg | In vivo MODE OF DELIVERYIntraperitoneal | In vivo METHODMicrodialysis analysis and LCMS analysis | In vivo RESULTSignificant amount of peptide crosses blood brain barrier after 12 minute and remain stable up to 80 | ACTIONShows potent analgesic behaviour | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONParkinson | RESPONSEStability/half life | RESULT80 minute | LABELNA | PMID 23127847 |
| B3pdbIDb3pdb_0200 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)DVAKVS | PEPTIDE SEQUENCE (3-letter)AspValAlaLysValSer | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH6 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0201 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)YSMVFVGIKL | PEPTIDE SEQUENCE (3-letter)TyrSerMetValPheValGlyIleLysLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH10 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0207 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)IGTLTT | PEPTIDE SEQUENCE (3-letter)IleGlyThrLeuThrThr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH6 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0235 | PEPTIDE NAMEPepH2 | PEPTIDE SEQUENCE (1-letter)KLFMALVAFLRFLT | PEPTIDE SEQUENCE (3-letter)LysLeuPheMetAlaLeuValAlaPheLeuArgPheLeuThr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH10 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEDerived from dengue virus capsid | SMILESNA | CELL LINEbEND cell line | In vitro CONCENTRATION5 microCi/ml | In vitro METHODGamma counter radioactivity measure for TcPz | In vitro RESULT9.32+/- 2.50 | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross blood brain barrier as well as shows membrane adsorption | TRANSPORT TYPETransmigration | SUBCELLULAR LOCALISATIONCan be migrated to liver, kidney etc. | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 28263555 |
| B3pdbIDb3pdb_0237 | PEPTIDE NAMEPepH4 | PEPTIDE SEQUENCE (1-letter)KSKAINVLRGFRKEIGRMLNILN | PEPTIDE SEQUENCE (3-letter)LysSerLysAlaIleAsnValLeuArgGlyPheArgLysGluIleGlyArgMetLeuAsnIleLeuAsn | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEDerived from dengue virus capsid | SMILESNA | CELL LINEbEND cell line | In vitro CONCENTRATION5 microCi/ml | In vitro METHODGamma counter radioactivity measure for TcPz | In vitro RESULT63.45+/- 1.90 | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross blood brain barrier as well as shows membrane adsorption | TRANSPORT TYPETransmigration | SUBCELLULAR LOCALISATIONCan be migrated to liver, kidney etc. | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 28263555 |
| B3pdbIDb3pdb_0239 | PEPTIDE NAMEPepH2 | PEPTIDE SEQUENCE (1-letter)KLFMALVAFLRFLT | PEPTIDE SEQUENCE (3-letter)LysLeuPheMetAlaLeuValAlaPheLeuArgPheLeuThr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH10 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEDerived from dengue virus capsid | SMILESNA | CELL LINEbEND cell line | In vitro CONCENTRATION5 microCi/ml | In vitro METHODGamma counter radioactivity measure for gaNODA | In vitro RESULT13.51 +/- 0.70 | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross blood brain barrier as well as shows membrane adsorption | TRANSPORT TYPETransmigration | SUBCELLULAR LOCALISATIONCan be migrated to liver, kidney etc. | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 28263555 |
| B3pdbIDb3pdb_0241 | PEPTIDE NAMEPepH4 | PEPTIDE SEQUENCE (1-letter)KSKAINVLRGFRKEIGRMLNILN | PEPTIDE SEQUENCE (3-letter)LysSerLysAlaIleAsnValLeuArgGlyPheArgLysGluIleGlyArgMetLeuAsnIleLeuAsn | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEDerived from dengue virus capsid | SMILESNA | CELL LINEbEND cell line | In vitro CONCENTRATION5 microCi/ml | In vitro METHODGamma counter radioactivity measure for gaNODA | In vitro RESULT60.79 +/- 2.60 | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross blood brain barrier as well as shows membrane adsorption | TRANSPORT TYPETransmigration | SUBCELLULAR LOCALISATIONCan be migrated to liver, kidney etc. | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 28263555 |
| B3pdbIDb3pdb_0260 | PEPTIDE NAMEDelta-sleep inducing | PEPTIDE SEQUENCE (1-letter)WAGGDASGE | PEPTIDE SEQUENCE (3-letter)Trp- Ala - Gly - Gly - Asp - Ala- Ser - Gly - Glu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH9 | PEPTIDE CONFORMATIONNA | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESBrain | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODMale albino adult rats | In vitro RESULTNA | ANIMAL MODELRIA, TLC | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 583452, 3840534 |
| B3pdbIDb3pdb_0268 | PEPTIDE NAMED-[Ala]-Peptide T-Am | PEPTIDE SEQUENCE (1-letter)aSTTTNYT-NH2 | PEPTIDE SEQUENCE (3-letter)NA | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODMice | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 3440215 |
| B3pdbIDb3pdb_0299 | PEPTIDE NAMEHAV6 | PEPTIDE SEQUENCE (1-letter)Ac-SHAVSS-NH2 | PEPTIDE SEQUENCE (3-letter)Ac-SerHisAlaValSerSerAsnHis-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH6 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEEC1 domain of E-cadherin | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODRat | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONdisrupt the BBB and enhance delivery of small molecules into the brain. | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 26705088 |
| B3pdbIDb3pdb_0311 | PEPTIDE NAMEP021 | PEPTIDE SEQUENCE (1-letter)Ac-DGGLAG-NH2 | PEPTIDE SEQUENCE (3-letter)Ac-AspGlyGlyLeuAlaGlyAsnHis-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH6 | PEPTIDE CONFORMATIONPentamer | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 27400746 |
| B3pdbIDb3pdb_0336 | PEPTIDE NAMEWSW | PEPTIDE SEQUENCE (1-letter)SYPGWSW | PEPTIDE SEQUENCE (3-letter)NA | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONNA | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELretro-inverso isomerization technique | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONquorum sensing peptide | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 28548480 |
| B3pdbIDb3pdb_0338 | PEPTIDE NAMEanalog 8 | PEPTIDE SEQUENCE (1-letter)YPW-(S,S)-AMBP-NH2 | PEPTIDE SEQUENCE (3-letter)H-Dmt-Pro-Trp-(S,S)-AMBF-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 28567476 |
| B3pdbIDb3pdb_0352 | PEPTIDE NAMEPepNeg | PEPTIDE SEQUENCE (1-letter)SGTQEEY | PEPTIDE SEQUENCE (3-letter)NA | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 29057814 |
| B3pdbIDb3pdb_0362 | PEPTIDE NAMEopioid glycopeptide | PEPTIDE SEQUENCE (1-letter)Y-D-TGFLS(β-O-Glc)-CONH2 | PEPTIDE SEQUENCE (3-letter)Tyr-D-Thr-Gly-Phe-Leu-Ser(β-O-Glc)-CONH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH6 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHOD | In vitro RESULTNA | ANIMAL MODELAdult Sprague-Dawley rats | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTHigh penetration | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 23127847 |
| B3pdbIDb3pdb_0386 | PEPTIDE NAMEIlantide | PEPTIDE SEQUENCE (1-letter)SGRKSSKMQA | PEPTIDE SEQUENCE (3-letter)SerGlyArgLysSerSerLysMetGlnAla | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH10 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEHEK-Blue IL-1β cells, HEK-Blue IL-6 cells | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODrat | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 24490798 |
| B3pdbIDb3pdb_0404 | PEPTIDE NAMEVasopressin | PEPTIDE SEQUENCE (1-letter)CYFQNCPRG | PEPTIDE SEQUENCE (3-letter)Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys1-Cys6 | PEPTIDE LENGTH9 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,bovine,mouse,rat | SMILESO=C(O)CNC(=O)[C@@H](NC(=O)[C@@H]4N(C(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](N)CSSC1)Cc2ccc(O)cc2)Cc3ccccc3)CCC(=O)N)CC(=O)N)CCC4)CCCNC(=[N@H])N | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional influx rate constant | RESULT0.00011 mL/(g x min) | LABELDirect iodination | PMID 17950952 |
| B3pdbIDb3pdb_0405 | PEPTIDE NAMEVasopressin | PEPTIDE SEQUENCE (1-letter)CYFQNCPRG | PEPTIDE SEQUENCE (3-letter)Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys1-Cys6 | PEPTIDE LENGTH9 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,bovine,mouse,rat | SMILESO=C(O)CNC(=O)[C@@H](NC(=O)[C@@H]4N(C(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](N)CSSC1)Cc2ccc(O)cc2)Cc3ccccc3)CCC(=O)N)CC(=O)N)CCC4)CCCNC(=[N@H])N | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODCapillary depletion | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEsaturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSECapillary depletion (parenchyma/serum) | RESULT0.00827 ml/g | LABELDirect iodination | PMID 17950952 |
| B3pdbIDb3pdb_0406 | PEPTIDE NAMEOxytocin | PEPTIDE SEQUENCE (1-letter)CYIQNCPLG | PEPTIDE SEQUENCE (3-letter)Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATIONCys1-Cys6 | PEPTIDE LENGTH9 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,bovine,mouse,rat | SMILESO=C(O)CNC(=O)[C@H](NC(=O)[C@H]3N(C(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](N)CSSC1)Cc2ccc(O)cc2)[C@@H](C)CC)CCC(=O)N)CC(=O)N)CCC3)CC(C)C | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSE% injected dose | RESULT0.018 %/g | LABELH3/C14 | PMID 10976589 |
| B3pdbIDb3pdb_0407 | PEPTIDE NAMEOxytocin | PEPTIDE SEQUENCE (1-letter)CYIQNCPLG | PEPTIDE SEQUENCE (3-letter)Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATIONCys1-Cys6 | PEPTIDE LENGTH9 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,bovine,mouse,rat | SMILESO=C(O)CNC(=O)[C@H](NC(=O)[C@H]3N(C(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](N)CSSC1)Cc2ccc(O)cc2)[C@@H](C)CC)CCC(=O)N)CC(=O)N)CCC3)CC(C)C | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEPeak response | RESULT1.09 µL/(g x min) | LABELH3/C14 | PMID 10976589 |
| B3pdbIDb3pdb_0408 | PEPTIDE NAMEOxytocin | PEPTIDE SEQUENCE (1-letter)CYIQNCPLG | PEPTIDE SEQUENCE (3-letter)Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATIONCys1-Cys6 | PEPTIDE LENGTH9 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,bovine,mouse,rat | SMILESO=C(O)CNC(=O)[C@H](NC(=O)[C@H]3N(C(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](N)CSSC1)Cc2ccc(O)cc2)[C@@H](C)CC)CCC(=O)N)CC(=O)N)CCC3)CC(C)C | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntracarotid injection | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEVolume of donor compartment | RESULT0.00815 ml/g | LABELH3/C14 | PMID 10976589 |
| B3pdbIDb3pdb_0415 | PEPTIDE NAMEOctreotide | PEPTIDE SEQUENCE (1-letter)fCFwKTCT | PEPTIDE SEQUENCE (3-letter)(D)Phe-Cys-Phe-(D)Trp-Lys-Thr-Cys-Thr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys2-Cys7 | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(O)[C@@H](NC(=O)[C@H]2NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](N)Cc1ccccc1)CSSC2)Cc3ccccc3)Cc5c4ccccc4nc5)CCCCN)[C@H](O)C)[C@H](O)C | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID NA |
| B3pdbIDb3pdb_0416 | PEPTIDE NAMEVapreotide | PEPTIDE SEQUENCE (1-letter)fCYwKVCW-NH2 | PEPTIDE SEQUENCE (3-letter)(D)Phe-Cys-Tyr-(D)Trp-Lys-Val-Cys-Trp-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys2-Cys7 | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)C(NC(=O)C2NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)Cc1ccccc1)CSSC2)Cc3ccc(O)cc3)Cc5c4ccccc4nc5)CCCCN)C(C)C)Cc7c6ccccc6nc7 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEnon saturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional influx rate constant | RESULT0.0000923 mL/(g x min) | LABELDirect iodination | PMID 1975697 |
| B3pdbIDb3pdb_0417 | PEPTIDE NAMEVapreotide | PEPTIDE SEQUENCE (1-letter)fCYwKVCW-NH2 | PEPTIDE SEQUENCE (3-letter)(D)Phe-Cys-Tyr-(D)Trp-Lys-Val-Cys-Trp-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys2-Cys7 | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)C(NC(=O)C2NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)Cc1ccccc1)CSSC2)Cc3ccc(O)cc3)Cc5c4ccccc4nc5)CCCCN)C(C)C)Cc7c6ccccc6nc7 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial distribution volume | RESULT0.0137 ml/g | LABELDirect iodination | PMID 1975697 |
| B3pdbIDb3pdb_0418 | PEPTIDE NAMEVapreotide | PEPTIDE SEQUENCE (1-letter)fCYwKVCW-NH2 | PEPTIDE SEQUENCE (3-letter)(D)Phe-Cys-Tyr-(D)Trp-Lys-Val-Cys-Trp-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys2-Cys7 | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)C(NC(=O)C2NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)Cc1ccccc1)CSSC2)Cc3ccc(O)cc3)Cc5c4ccccc4nc5)CCCCN)C(C)C)Cc7c6ccccc6nc7 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEhalf life, serum | RESULT1.05 min | LABELDirect iodination | PMID 1975697 |
| B3pdbIDb3pdb_0419 | PEPTIDE NAMEVapreotide | PEPTIDE SEQUENCE (1-letter)fCYwKVCW-NH2 | PEPTIDE SEQUENCE (3-letter)(D)Phe-Cys-Tyr-(D)Trp-Lys-Val-Cys-Trp-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys2-Cys7 | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)C(NC(=O)C2NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)Cc1ccccc1)CSSC2)Cc3ccc(O)cc3)Cc5c4ccccc4nc5)CCCCN)C(C)C)Cc7c6ccccc6nc7 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODEfflux study ICU | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEhalf life, brain | RESULT24 min | LABELDirect iodination | PMID 1975697 |
| B3pdbIDb3pdb_0420 | PEPTIDE NAMEVapreotide | PEPTIDE SEQUENCE (1-letter)fCYwKVCW-NH2 | PEPTIDE SEQUENCE (3-letter)(D)Phe-Cys-Tyr-(D)Trp-Lys-Val-Cys-Trp-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys2-Cys7 | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)C(NC(=O)C2NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)Cc1ccccc1)CSSC2)Cc3ccc(O)cc3)Cc5c4ccccc4nc5)CCCCN)C(C)C)Cc7c6ccccc6nc7 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODEfflux study ICU | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEsaturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEBrain elemination rate constant | RESULT0.029 min-1 | LABELDirect iodination | PMID 1975697 |
| B3pdbIDb3pdb_0421 | PEPTIDE NAMEVapreotide | PEPTIDE SEQUENCE (1-letter)fCYwKVCW-NH2 | PEPTIDE SEQUENCE (3-letter)(D)Phe-Cys-Tyr-(D)Trp-Lys-Val-Cys-Trp-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys2-Cys7 | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)C(NC(=O)C2NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)Cc1ccccc1)CSSC2)Cc3ccc(O)cc3)Cc5c4ccccc4nc5)CCCCN)C(C)C)Cc7c6ccccc6nc7 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEnon saturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEPermeability surface area cofficient | RESULT20.3 µL/(g x min) | LABELDirect iodination | PMID 1975697 |
| B3pdbIDb3pdb_0422 | PEPTIDE NAMEVapreotide | PEPTIDE SEQUENCE (1-letter)fCYwKVCW-NH2 | PEPTIDE SEQUENCE (3-letter)(D)Phe-Cys-Tyr-(D)Trp-Lys-Val-Cys-Trp-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys2-Cys7 | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)C(NC(=O)C2NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)Cc1ccccc1)CSSC2)Cc3ccc(O)cc3)Cc5c4ccccc4nc5)CCCCN)C(C)C)Cc7c6ccccc6nc7 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODHPLC | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSE% injected dose | RESULT41.6 %/g | LABELDirect iodination | PMID 1975697 |
| B3pdbIDb3pdb_0423 | PEPTIDE NAMEVapreotide | PEPTIDE SEQUENCE (1-letter)fCYwKVCW-NH2 | PEPTIDE SEQUENCE (3-letter)(D)Phe-Cys-Tyr-(D)Trp-Lys-Val-Cys-Trp-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys2-Cys7 | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)C(NC(=O)C2NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)Cc1ccccc1)CSSC2)Cc3ccc(O)cc3)Cc5c4ccccc4nc5)CCCCN)C(C)C)Cc7c6ccccc6nc7 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODHPLC | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSE% injected dose | RESULT36.9 %/g | LABELDirect iodination | PMID 1975697 |
| B3pdbIDb3pdb_0478 | PEPTIDE NAMEDeltorphin I, [D-Ala | PEPTIDE SEQUENCE (1-letter)YaFDVVG-NH2 | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Ala-Phe-Asp-Val-Val-Gly-NH2 | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEGila monster | SMILESO=C(N)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)Cc1ccc(O)cc1)C)Cc2ccccc2)CC(=O)O)C(C)C)C(C)C | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODBMEC | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYBMEC | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPE(saturable) | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEPermeability coefficient | RESULT0.00003788 cm/s | LABELNA | PMID 9152390 |
| B3pdbIDb3pdb_0479 | PEPTIDE NAMEDeltorphin II, [D-Al | PEPTIDE SEQUENCE (1-letter)YaFEVVG-NH2 | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Ala-Phe-Glu-Val-Val-Gly-NH2 | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,mouse,rat | SMILESO=C(N)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)Cc1ccc(O)cc1)C)Cc2ccccc2)CCC(=O)O)C(C)C)C(C)C | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODBMEC | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYBMEC | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPE(saturable) | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEPermeability coefficient | RESULT0.00003915 cm/s | LABELNA | PMID 9152390 |
| B3pdbIDb3pdb_0575 | PEPTIDE NAMEBiphalin | PEPTIDE SEQUENCE (1-letter)YaGF-NH-NH-FGaY | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Ala-Gly-Phe-NH-NH-Phe-Gly-(D)Ala-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEcat | SMILESO=C(N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)NNC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C)Cc2ccccc2)Cc3ccccc3)C)[C@@H](N)Cc4ccc(O)cc4 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.001 mL/(g x min) | LABELDirect iodination | PMID 11714884 |
| B3pdbIDb3pdb_0576 | PEPTIDE NAMEBiphalin | PEPTIDE SEQUENCE (1-letter)YaGF-NH-NH-FGaY | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Ala-Gly-Phe-NH-NH-Phe-Gly-(D)Ala-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEcat | SMILESO=C(N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)NNC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C)Cc2ccccc2)Cc3ccccc3)C)[C@@H](N)Cc4ccc(O)cc4 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial distribution vaolume | RESULT0.0097 ml/g | LABELDirect iodination | PMID 11714884 |